Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised

Celldex Therapeutics, Inc.

Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.
Non-employee director annual award limit raised to $750K ($1.2M for new directors) effective after stockholder approval.
All eight director nominees elected, including CEO Anthony Marucci and Chair Karen Shoos, with over 54.6M votes for each.
Advisory say-on-pay vote approved with 54.2M for, 0.9M against; auditor ratification passed with 57.8M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.